CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
接受 T 细胞重定向治疗的多发性骨髓瘤患者的感染风险：对临床医生的呼吁
英文原题：Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians.
查看英文原题
Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
T细胞重定向疗法，如CAR-T 细胞和双特异性抗体，正在成为治疗复发难治性多发性骨髓瘤（MM）的一类新型免疫治疗药物。其使用与感染性不良事件风险增加相关，这一风险由血细胞减少、低丙种球蛋白血症和T细胞耗竭所助长。多项正在进行的临床试验和真实世界研究正在调查T细胞疗法的安全性，凸显了预防和监测感染风险的策略需求。推荐的风险缓解措施包括静脉注射免疫球蛋白补充、充分的预防性治疗、疫苗接种以及仔细评估以早期诊断和治疗感染。在此，我们总结了已获批和正在开发中的用于治疗MM的T细胞重定向疗法感染风险的现有数据。
展开英文摘要原文
T-cell redirecting therapies such as chimeric antigen receptor T-cells and bispecific antibodies, are emerging as a novel class of immunotherapeutic agents for treatment of relapsed refractory multiple myeloma (MM). Their use is associated with an increased risk of infectious adverse events, fostered by cytopenias, hypogammaglobulinemia and T-cell exhaustion.
Multiple ongoing clinical trials and real-world studies are investigating safety of T-cell therapy, highlighting the need for strategies to prevent and monitor the risk of infection. Recommended measures for risk mitigation include intravenous immunoglobulin supplementation, adequate prophylaxis therapy, vaccination and careful assessment for early diagnosis and treatment of infection.
Here, we summarize available data on the risk of infections with approved and under development T-cell redirecting therapies for the treatment of MM.
论文信息
- 作者
- Lupia T、Cani L、Bringhen S、De Rosa FG、Bruno B、Mikulska M、Corcione S、Mina R
- 第一作者单位
- Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.Italy
- 通讯作者单位
- Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Turin, Italy. Electronic address: roberto.mina.rm@gmail.com.Italy
- 文献类型
- 综述
- 期刊
- Clinical lymphoma, myeloma & leukemia2024 Sep
- 原文标识
- PubMed 38849284 · DOI 10.1016/j.clml.2024.05.002